BibTex RIS Cite

Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?

Year 2019, Volume: 76 Issue: 1, 99 - 108, 01.03.2019

Abstract

Hemostazın sağlanması ve hastalıkların gelişmesinde belirgin etkisi olan bağırsak mikrobiyotası insan gastrointestinal sisteminde yaşayan kompleks ve dinamik bir mikroorganizma topluluğundan oluşmaktadır. Bağırsak hemostazın devamlılığının sağlanmasında ve patojen mikroorganizmalara karşı korunmada kritik rol oynar. Bebeklik döneminde insan bağırsak mikrobiyotası gelişimine çok sayıda faktör etki etmektedir. İnsan mikrobiyom projesi ile başlayan hastalıklara yaklaşım, yeni patogenezleri ortaya koymaktadır. Bağırsak mikrobiyotasının değişimi disbiyozis birçok inflamatuvar hastalığın patogenizi ile ilişkilidir. Antibiyotikler mikrobiyota gelişiminde ve değişimindeki en önemli faktörlerden biridir. Çocukluk çağı obezitesinin prevalansındaki artış sağlık çalışanlarının karşılaştığı en büyük sorunlardan biridir. Obezite riskini azaltmada etkili stratejilere ihtiyaç duyulmaktadır. Bu stratejilerin geliştirilmesi ise obezite gelişiminde rol oynayan faktörlerin daha iyi anlaşılmasına bağlıdır. Son yıllardaki veriler, obeziteye neden olan risklerin bebeklik döneminde başlayabileceğini ve çocukluk çağında fazla kilolu olmanın, ileri yaşlardaki obezitenin güçlü bir tahmini faktör olabileceğini göstermektedir. Özellikle iki yaşına kadar kullanılan antibiyotiklerin çocukluk çağında fazla kilo veya obezite ile arasındaki ilişki epidemiyolojik çalışmalar ile ortaya konmaktadır. Antibiyotik kullanımına bağlı gelişen disbiyozisin obezite zeminini nasıl ortaya çıkardığı ancak iyi dizayn edilmiş hayvan deneyleri ile ortaya konulabilir. Obez bireyler zayıf olanlara kıyasla bağırsak mikrobiyota içeriğinde belirgin farklılıklar gösterirler. Obezite, Firmicutes filumundaki artış ve Bacteroidetes filumundaki azalış ile ilişkilidir. Obezite ile ilişkili bağırsak mikrobiyotası, bağırsakta besinlerden alınan enerjiyi de arttırmaktadır. Bugün için elde edilen verilere göre antibiyotikler, mikrobiyota bileşiminde değişikliğe neden olabileceği gibi farklı fizyolojik mekanizmalar ve gen düzeyindeki değişikliklerle de obezite zeminini hazırlayabilirler. Bu derlemede antibiyotik kullanımına bağlı oluşan disbiyozisin etkisine bağlı olarak gelişen obezitenin nedenleri tartışılmıştır

References

  • Turnbaugh, PJ, Ley RE, Hamady M, Fraser- Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature, 2007; 449(7164): 804-10.
  • Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on humanhealth and diseases. Intern Jour of Mol Sci, 2015; 16(4): 7493-519.
  • Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS. et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355–9 doi:10.1126/science.1124234.
  • Natividad JMM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications. Pharmacol. Res. 2013; 69: 42–51.
  • den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short- chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013; 54: 2325–40.
  • Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016; 535: 85–93.
  • Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science, 2016; 352: 539–44.
  • Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science,
  • Monasta L, Batty GD, Cattaneo A, Lutje V, Ronfani L, Van Lenthe FJ, et al. Early life determinants of overweight and obesity. Obes Rev. 2010;11:695– 708.
  • Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World Jour of Gastro, 2005; 11: 1131–40.
  • Makino H, Kushiro A, Ishikawa E, Kubota H, Gawad A, Sakai T, et al. Mother-to-infant transmission of intestinal bifidobacterial strains has an impact on the early development of vaginally delivered infant’s microbiota. PLoS One. 2013;8:e78331.
  • Munyaka PM, Khafipour E, Ghia JE. External influence of early childhood establishment of gut microbiota and subsequent health implications. Front Pediatr. 2014; 2: 109-18.
  • Ferrer M, Mendez Garcia C, Rojo D, Barbas C, Van de Merwe JP, Stegeman, J, et al. The resident faecal flora is determined by genetic characteristics of the host. Implications for crohn’s disease? Antonie Van Leeuwenhoek, 1983; 49: 119-24.
  • Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiological Reviews, 2010; 90(3): 859-904.
  • Süzük S. Helicobacter pylori Tedavisinin Mikrobiyota Üzerine Etkisi. Doktora Tezi, Gazi Üniversitesi Sağlık Bilimleri Enstitüsü, 2015.
  • Thuny F, Richet H, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One. 2010; 5: e9074.
  • Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014; 68: 217–35.
  • Panda S, El khader I, Casellas F, Lopez Vivancos J, Garcia Cors M, Santiago A, et al. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014; 9: e95476.
  • Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014; 124: 4212–18.
  • Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010; 5: e9836.
  • Kim DH. Gut Microbiota-Mediated Drug- Antibiotic interactions. Drug Metab Dispos. 2015; 43(10): 1581-9.
  • Liao X, Li B, Zou R, Dai Y, Xie S, Yuan B. Biodegradation of antibiotic ciprofloxacin: pathways, influential factors, and bacterial community structure. Environ Sci Pollut Res Int. 2016; 23(8): 7911-18.
  • Raymond F, Ouameur AA, Déraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10(3): 707-20.
  • Turta O, Rautava S. Antibiotics, obesity and the link to microbes - what are we doing to our children? BMC Med. 2016; 14: 57-63.
  • Persaud RR, Azad MB, Chari RS, Sears MR, Becker AB, Kozyrskyj AL. Perinatal antibiotic exposure of neonates in Canada and associated risk factors: a population-based study. J Matern Fetal Neonatal Med. 2015; 28: 1190–5.
  • Polin RA, Committee on Fetus and Newborn, Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics.
  • Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014; 165: 23–9.
  • Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 2014; 38: 1290–8.
  • Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014; 68: 1063–9.
  • Rasmussen SH, Shrestha S, Bjerregaard LG, Ängquist LH, Baker JL, Jess T, Allin KH. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis. Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13230. [Epub ahead of print].
  • Rautava S, Ruuskanen O, Ouwehand A, Salminen S, Isolauri E. The hygiene hypothesis of atopic disease - an extended version. J Pediatr Gastroenterol Nutr. 2004; 38: 378–88.
  • Semic-Jusufagic A, Belgrave D, Pickles A, Telcian AG, Bakhsoliani E, Sykes A, et al. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: apopulation-based birth cohort study. Lancet Respir Med. 2014; 2: 621–30.
  • Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011; 60: 49–54.
  • Lutz TA, Bueter M. Physiological mechanisms behind Roux-en-Y gastric bypass surgery. Dig Surg. 2014; 31: 13–24.
  • Kugelberg E. Surgery: Altered gut microbiota trigger weight loss. Nat Rev Endocrinol. 2013; 9: 314-9.
  • Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013; 98: 16–24.
  • Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015; 22: 228–38.

The Bridge Between Antibiotic Use and Obesity: Is It a Microbiota?

Year 2019, Volume: 76 Issue: 1, 99 - 108, 01.03.2019

Abstract

The human gastrointestinal tract harbors a complex and dynamic population of microorganisms, the gut microbiota, which exert a marked influence on the host during homeostasis and disease. Intestinal bacteria play a crucial role in maintaining immune and metabolic homeostasis and protecting against pathogens. Many factors contribute to the establishment of the human gut microbiota during infancy. The approach to diseases that begin with the human microbiom project reveals new pathogenesis. Altered gut bacterial composition dysbiosis has been associated with the pathogenesis of many inflammatory diseases. Antibiotics are one of the most important factors in the development and change of microbiota. The increasing prevalence of childhood obesity is one of the greatest challenges facing medical professionals. Effective strategies for reducing the risk of obesity are desperately needed. The development of these strategies is dependent on a better understanding of the factors that play a role in the development of obesity. The data in recent years show that the risks of obesity can start in infancy and that being overweight in childhood is a strong predictor of obesity in old age. Particularly, the relationship between the antibiotics used up to the age of two and their childhood overweight or obesity is revealed by fazla kilo veya obezite ile arasındaki ilişki epidemiyolojik çalışmalar ile ortaya konmaktadır. Antibiyotik kullanımına bağlı gelişen disbiyozisin obezite zeminini nasıl ortaya çıkardığı ancak iyi dizayn edilmiş hayvan deneyleri ile ortaya konulabilir. Obez bireyler zayıf olanlara kıyasla bağırsak mikrobiyota içeriğinde belirgin farklılıklar gösterirler. Obezite, Firmicutes filumundaki artış ve Bacteroidetes filumundaki azalış ile ilişkilidir. Obezite ile ilişkili bağırsak mikrobiyotası, bağırsakta besinlerden alınan enerjiyi de arttırmaktadır. Bugün için elde edilen verilere göre antibiyotikler, mikrobiyota bileşiminde değişikliğe neden olabileceği gibi farklı fizyolojik mekanizmalar ve gen düzeyindeki değişikliklerle de obezite zeminini hazırlayabilirler. Bu derlemede antibiyotik kullanımına bağlı oluşan disbiyozisin etkisine bağlı olarak gelişen obezitenin nedenleri tartışılmıştır

References

  • Turnbaugh, PJ, Ley RE, Hamady M, Fraser- Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature, 2007; 449(7164): 804-10.
  • Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on humanhealth and diseases. Intern Jour of Mol Sci, 2015; 16(4): 7493-519.
  • Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS. et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355–9 doi:10.1126/science.1124234.
  • Natividad JMM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications. Pharmacol. Res. 2013; 69: 42–51.
  • den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short- chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013; 54: 2325–40.
  • Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016; 535: 85–93.
  • Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science, 2016; 352: 539–44.
  • Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science,
  • Monasta L, Batty GD, Cattaneo A, Lutje V, Ronfani L, Van Lenthe FJ, et al. Early life determinants of overweight and obesity. Obes Rev. 2010;11:695– 708.
  • Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World Jour of Gastro, 2005; 11: 1131–40.
  • Makino H, Kushiro A, Ishikawa E, Kubota H, Gawad A, Sakai T, et al. Mother-to-infant transmission of intestinal bifidobacterial strains has an impact on the early development of vaginally delivered infant’s microbiota. PLoS One. 2013;8:e78331.
  • Munyaka PM, Khafipour E, Ghia JE. External influence of early childhood establishment of gut microbiota and subsequent health implications. Front Pediatr. 2014; 2: 109-18.
  • Ferrer M, Mendez Garcia C, Rojo D, Barbas C, Van de Merwe JP, Stegeman, J, et al. The resident faecal flora is determined by genetic characteristics of the host. Implications for crohn’s disease? Antonie Van Leeuwenhoek, 1983; 49: 119-24.
  • Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiological Reviews, 2010; 90(3): 859-904.
  • Süzük S. Helicobacter pylori Tedavisinin Mikrobiyota Üzerine Etkisi. Doktora Tezi, Gazi Üniversitesi Sağlık Bilimleri Enstitüsü, 2015.
  • Thuny F, Richet H, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One. 2010; 5: e9074.
  • Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014; 68: 217–35.
  • Panda S, El khader I, Casellas F, Lopez Vivancos J, Garcia Cors M, Santiago A, et al. Short-term effect of antibiotics on human gut microbiota. PLoS One. 2014; 9: e95476.
  • Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014; 124: 4212–18.
  • Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010; 5: e9836.
  • Kim DH. Gut Microbiota-Mediated Drug- Antibiotic interactions. Drug Metab Dispos. 2015; 43(10): 1581-9.
  • Liao X, Li B, Zou R, Dai Y, Xie S, Yuan B. Biodegradation of antibiotic ciprofloxacin: pathways, influential factors, and bacterial community structure. Environ Sci Pollut Res Int. 2016; 23(8): 7911-18.
  • Raymond F, Ouameur AA, Déraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10(3): 707-20.
  • Turta O, Rautava S. Antibiotics, obesity and the link to microbes - what are we doing to our children? BMC Med. 2016; 14: 57-63.
  • Persaud RR, Azad MB, Chari RS, Sears MR, Becker AB, Kozyrskyj AL. Perinatal antibiotic exposure of neonates in Canada and associated risk factors: a population-based study. J Matern Fetal Neonatal Med. 2015; 28: 1190–5.
  • Polin RA, Committee on Fetus and Newborn, Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics.
  • Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014; 165: 23–9.
  • Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 2014; 38: 1290–8.
  • Bailey LC, Forrest CB, Zhang P, Richards TM, Livshits A, DeRusso PA. Association of antibiotics in infancy with early childhood obesity. JAMA Pediatr. 2014; 68: 1063–9.
  • Rasmussen SH, Shrestha S, Bjerregaard LG, Ängquist LH, Baker JL, Jess T, Allin KH. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis. Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13230. [Epub ahead of print].
  • Rautava S, Ruuskanen O, Ouwehand A, Salminen S, Isolauri E. The hygiene hypothesis of atopic disease - an extended version. J Pediatr Gastroenterol Nutr. 2004; 38: 378–88.
  • Semic-Jusufagic A, Belgrave D, Pickles A, Telcian AG, Bakhsoliani E, Sykes A, et al. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: apopulation-based birth cohort study. Lancet Respir Med. 2014; 2: 621–30.
  • Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011; 60: 49–54.
  • Lutz TA, Bueter M. Physiological mechanisms behind Roux-en-Y gastric bypass surgery. Dig Surg. 2014; 31: 13–24.
  • Kugelberg E. Surgery: Altered gut microbiota trigger weight loss. Nat Rev Endocrinol. 2013; 9: 314-9.
  • Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013; 98: 16–24.
  • Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015; 22: 228–38.
There are 37 citations in total.

Details

Primary Language Turkish
Journal Section Collection
Authors

Serap Süzük Yıldız This is me

Dilek Öztaş This is me

Publication Date March 1, 2019
Published in Issue Year 2019 Volume: 76 Issue: 1

Cite

APA Yıldız, S. S., & Öztaş, D. (2019). Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?. Türk Hijyen Ve Deneysel Biyoloji Dergisi, 76(1), 99-108.
AMA Yıldız SS, Öztaş D. Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?. Turk Hij Den Biyol Derg. March 2019;76(1):99-108.
Chicago Yıldız, Serap Süzük, and Dilek Öztaş. “Antibiyotik Kullanımı Ve Obezite Arasındaki Köprü: Mikrobiyota mı?”. Türk Hijyen Ve Deneysel Biyoloji Dergisi 76, no. 1 (March 2019): 99-108.
EndNote Yıldız SS, Öztaş D (March 1, 2019) Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?. Türk Hijyen ve Deneysel Biyoloji Dergisi 76 1 99–108.
IEEE S. S. Yıldız and D. Öztaş, “Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?”, Turk Hij Den Biyol Derg, vol. 76, no. 1, pp. 99–108, 2019.
ISNAD Yıldız, Serap Süzük - Öztaş, Dilek. “Antibiyotik Kullanımı Ve Obezite Arasındaki Köprü: Mikrobiyota mı?”. Türk Hijyen ve Deneysel Biyoloji Dergisi 76/1 (March 2019), 99-108.
JAMA Yıldız SS, Öztaş D. Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?. Turk Hij Den Biyol Derg. 2019;76:99–108.
MLA Yıldız, Serap Süzük and Dilek Öztaş. “Antibiyotik Kullanımı Ve Obezite Arasındaki Köprü: Mikrobiyota mı?”. Türk Hijyen Ve Deneysel Biyoloji Dergisi, vol. 76, no. 1, 2019, pp. 99-108.
Vancouver Yıldız SS, Öztaş D. Antibiyotik Kullanımı ve Obezite Arasındaki Köprü: Mikrobiyota mı?. Turk Hij Den Biyol Derg. 2019;76(1):99-108.